Kingsview Wealth Management LLC Reduces Position in Amgen Inc. $AMGN

Kingsview Wealth Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.2% in the 4th quarter, Holdings Channel reports. The fund owned 37,812 shares of the medical research company’s stock after selling 2,920 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Amgen were worth $12,376,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of AMGN. Capital World Investors grew its stake in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares in the last quarter. Geode Capital Management LLC grew its stake in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares during the period. National Bank of Canada FI grew its stake in shares of Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after buying an additional 863,216 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock valued at $383,254,000 after buying an additional 567,400 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $336.06 on Thursday. The firm’s 50 day moving average price is $343.32 and its 200-day moving average price is $345.27. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The firm has a market cap of $181.37 billion, a P/E ratio of 23.39, a P/E/G ratio of 3.37 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the business posted $4.90 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts predict that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.15%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the subject of several analyst reports. Jefferies Financial Group initiated coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Rothschild & Co Redburn increased their price target on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Leerink Partners reissued a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Guggenheim dropped their price target on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Finally, Royal Bank Of Canada increased their price target on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $355.19.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.